Clinical Trial Update: Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of AZD4831 in heart failure was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• AZD4831 (AZD4831)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2021-07-19